Global licensing hub exposes systemic barriers to equitable biotherapeutic access, urging collective governance reforms
Original framing: “The Medicines Patent Pool is improving access to essential medication where it’s most needed, but does it make economic sense?” — The Conversation - Global
Patients, frontline health workers, and civil‑society groups in the Global South are rarely quoted in discussions about the MPP, despite bearing the brunt of access inequities. Their lived experiences reveal gaps in supply chains, cultural acceptability, and trust that licensing agreements alone cannot fix. Elevating these voices reshapes the agenda toward participatory governance.
The Medicines Patent Pool operates within a legacy of colonial‑era intellectual‑property regimes that privilege profit over public health, a reality obscured by its market‑friendly framing.
Integrating indigenous stewardship principles, historical lessons from HIV/AIDS activism, and cross‑cultural models of collective innovation reveals that voluntary licensing alone cannot achieve equitable access. Robust solutions require mandatory technology transfer, reinforced TRIPS flexibilities, a globally funded health commons, and community‑driven procurement—all anchored in participatory governance that amplifies marginalised voices. By aligning scientific rigor with artistic‑spiritual values and future scenario planning, the system can shift from a profit‑centric hub to a resilient, justice‑oriented health commons.